Navigation Links
New partnership brings more personalized cancer treatment to Philadelphia
Date:7/23/2014

(PHILADELPHIA) The Worldwide Innovative Networking in personalized cancer medicine, (the WIN consortium), recently announced that the Sidney Kimmel Cancer Center at Thomas Jefferson University will be one of its six new members the only member of this prestigious group in the Tri-State Area. The goal of WIN is to speed the delivery of innovative personalized medicine to the patient by forging collaborations between partners in academia, industry, and patient advocacy.

"Our participation in the WIN consortium means Jefferson cancer patients will have access to worldwide clinical trials on promising and individualized therapies," says Massimo Cristofanilli, M.D., Director of the Jefferson Breast Care Center. "It creates a global oncology, a technologically advanced approach to managing our patients."

The consortium was formed in 2010 and today is made up of 24 member cancer centers across 16 countries and four continents. It includes four major technology partners, three pharmaceutical companies and five non-profit or patient advocacy groups. The goal of the network is to facilitate collaboration between medical centers and industry with the aim of speeding the delivery of personalized medicine to cancer patients.

The WIN collaborators "bring immense capabilities and expertise that will be invaluable in building our shared capacity to impact the lives of cancer patients around the world through advancing personalized cancer medicine," says John Mendelsohn, M.D., Chairman of the WIN Consortium.

WIN's first and ongoing clinical trial, WINTHER, is open to all patients with solid tumors. WINTHER looks at DNA aberrations/mutations in the tumor but also investigates the transcriptome by looking at the differential RNA expression levels between tumor and normal tissue of the same patient. To date, many targeted therapies are delivered only to those patients showing a mutation in a specific gene. However, some patients may have a normal-looking gene that is being produced at abnormal levels, which is when looking at RNA can be helpful. Using this approach, researchers will be able to match a greater proportion of patients with experimental therapies.

As a WIN member, Jefferson will have the opportunity to suggest novel trials for the consortium's consideration.

The collaboration will also allow Jefferson to offer some of its most exciting approaches such as circulating tumor cell (CTCs) diagnostics, also called liquid biopsy, for tracking the progress of metastatic disease to the international community.

"We can't beat cancer alone. It will take partnerships across institutions, across industries, and across the globe to make sure every patient has the best shot at the right therapy," says Richard Pestell, M.D., Ph.D., Director of the Sidney Kimmel Cancer Center.


'/>"/>

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related biology news :

1. University of Strathclyde and NYU join in landmark research and academic partnership
2. An international partnership takes the stage at ESOF 2014
3. Structural Genomics Consortium and CHDI Foundation announce new partnership
4. Full power: Alternative energy partnerships flourish in Asia
5. New international partnership aims to unlock wheats potential
6. Iowa State Universitys Wintersteen talks partnerships at national science meeting
7. MRC funds BREATHE Africa partnership
8. EcoHealth Alliance and Bat Conservation International forge partnership to work on global bat conservation and public health issues
9. Anglo-French partnership develops guidance on future management of English Channel
10. Bold new partnership launches to harness potential of data scientists and big data
11. Wiley and EMBO announce expanded partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017  Rhythm, a biopharmaceutical ... deficiencies that result in life-threatening metabolic disorders, ... million mezzanine round of financing with existing ... Capital, New Enterprise Associates, Pfizer Venture Investments, ... healthcare investment fund. Rhythm will use the ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... extended its industry leading Biochemistry Services specifically targeting the rapidly growing needs ... methods for the biochemical and biosimilar characterization , product-related impurity characterization, ...
(Date:2/15/2017)... ... February 15, 2017 , ... Park Systems , a leader in Atomic ... software that drastically boosts productivity with single click reliable nanoscale images, is now available ... setting up and taking the image once done manually by the operator producing high ...
(Date:2/15/2017)...  NASA provider SpaceX is scheduled to launch its ... Station  no earlier than 10:01 a.m. EST Saturday, Feb. ... 8:30 a.m. on NASA Television and the agency,s website. ... lift off on the company,s Falcon 9 rocket from ... Center in Florida , ...
Breaking Biology Technology: